Long-term treatment of EoE: BOS, BOT, and PPIs

Long-term treatment of Eosinophilic Esophagitis (EoE) focuses on preventing relapse and complications like fibrostenosis by maintaining remission through sustained therapy. Recent studies have evaluated three main therapeutic options: Budesonide Oral Suspension (BOS), Budesonide Orodispersible Tablets (BOT), and Proton Pump Inhibitors (PPIs). Here’s a detailed breakdown of their efficacy and safety:

1. Budesonide Oral Suspension (BOS):

• Efficacy: A four-year U.S. multicenter open-label continuation study demonstrated that BOS maintained remission in over 50% of treated patients with EoE.
• Safety:
• Some evidence of adrenal suppression was observed, which is a potential side effect of corticosteroids.
• Bone mineral density remained stable in adolescents, suggesting that BOS did not significantly affect bone health over the study period.
• Mild esophageal candidiasis was reported as a side effect in some patients.

2. Budesonide Orodispersible Tablets (BOT):

• Efficacy: A three-year European study found BOT to be highly effective, maintaining remission in a greater proportion of patients compared to BOS.
• Safety:
• Minimal cortisol suppression was observed, indicating a lower risk of systemic corticosteroid side effects compared to BOS.
• Similar to BOS, mild esophageal candidiasis was reported in some cases.

3. Proton Pump Inhibitors (PPIs):

• Efficacy: An updated systematic review showed that PPIs achieved remission in a substantial number of patients with EoE. PPIs are thought to work by reducing esophageal acid exposure and possibly through anti-inflammatory mechanisms.
• Maintenance: Dose tapering was found to successfully maintain remission in most responders, making PPIs a viable long-term strategy for many patients.
• Safety: PPIs are generally well-tolerated, with fewer systemic side effects compared to corticosteroids.

Key Insights from the Studies:

• Effectiveness: Both BOS and BOT are effective in maintaining long-term remission in EoE, with BOT showing slightly better outcomes in terms of remission rates and lower cortisol suppression.
• Side Effects: Mild esophageal candidiasis is a common side effect of both BOS and BOT, while PPIs are associated with fewer side effects overall.
• Patient Monitoring: Long-term therapy requires ongoing monitoring, especially in younger populations, to assess for potential side effects like adrenal suppression or bone health concerns.
• Non-Responders: For patients who do not respond to these therapies, alternative strategies remain a clinical priority.

Clinical Implications:

• Treatment Personalization: The choice between BOS, BOT, and PPIs should be individualized based on patient response, safety profiles, and preferences.
• Safety Monitoring: Regular monitoring for potential adverse effects, such as adrenal suppression, bone density changes, and esophageal candidiasis, is crucial, particularly in younger patients.
• Research Priorities: Further studies are needed to explore alternative treatments for non-responders and to optimize long-term management strategies.

In summary, BOS, BOT, and PPIs are all effective options for the long-term management of EoE, with each therapy offering distinct benefits and risks. BOT appears to have a slight advantage in terms of efficacy and safety over BOS, while PPIs provide a non-corticosteroid alternative with good remission rates and minimal side effects.